PortalPublikationenMutagenesis by retroviral transgene insertion

Mutagenesis by retroviral transgene insertion

Standard

Mutagenesis by retroviral transgene insertion : risk assessment and potential alternatives. / Baum, Christopher; Fehse, Boris.

in: Current opinion in molecular therapeutics, Jahrgang 5, Nr. 5, 10.2003, S. 458-62.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Baum, C & Fehse, B 2003, 'Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives', Current opinion in molecular therapeutics, Jg. 5, Nr. 5, S. 458-62.

APA

Baum, C., & Fehse, B. (2003). Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives. Current opinion in molecular therapeutics, 5(5), 458-62.

Vancouver

Baum C, Fehse B. Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives. Current opinion in molecular therapeutics. 2003 Okt;5(5):458-62.

Bibtex

@article{ea99ff19a11c4111b1013a0b434bbdd3,
title = "Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives",
abstract = "Focus on retroviral gene transfer into hematopoietic cells has previously led to a proposed classification of side effects and discussion of issues related to combinatorial toxicity (including oncogenicity) of genetic interventions. Recent data underline that this discussion has to be broadened to any type of stable transfer technology. This review summarizes insights obtained in cell culture and animal models that were specifically designed to evaluate side effects of transgene insertion and new approaches of insertion site targeting. Ongoing research aims to reduce side effects of therapeutic transgene insertion by dose optimization and definition of contributing risk factors.",
keywords = "Base Sequence, Gene Dosage, Gene Transfer Techniques, Genetic Vectors/genetics, Humans, Mutagenesis, Neoplasms/physiopathology, Recombination, Genetic, Retroviridae/genetics, Risk Assessment, Transgenes",
author = "Christopher Baum and Boris Fehse",
year = "2003",
month = oct,
language = "English",
volume = "5",
pages = "458--62",
number = "5",

}

RIS

TY - JOUR

T1 - Mutagenesis by retroviral transgene insertion

T2 - risk assessment and potential alternatives

AU - Baum, Christopher

AU - Fehse, Boris

PY - 2003/10

Y1 - 2003/10

N2 - Focus on retroviral gene transfer into hematopoietic cells has previously led to a proposed classification of side effects and discussion of issues related to combinatorial toxicity (including oncogenicity) of genetic interventions. Recent data underline that this discussion has to be broadened to any type of stable transfer technology. This review summarizes insights obtained in cell culture and animal models that were specifically designed to evaluate side effects of transgene insertion and new approaches of insertion site targeting. Ongoing research aims to reduce side effects of therapeutic transgene insertion by dose optimization and definition of contributing risk factors.

AB - Focus on retroviral gene transfer into hematopoietic cells has previously led to a proposed classification of side effects and discussion of issues related to combinatorial toxicity (including oncogenicity) of genetic interventions. Recent data underline that this discussion has to be broadened to any type of stable transfer technology. This review summarizes insights obtained in cell culture and animal models that were specifically designed to evaluate side effects of transgene insertion and new approaches of insertion site targeting. Ongoing research aims to reduce side effects of therapeutic transgene insertion by dose optimization and definition of contributing risk factors.

KW - Base Sequence

KW - Gene Dosage

KW - Gene Transfer Techniques

KW - Genetic Vectors/genetics

KW - Humans

KW - Mutagenesis

KW - Neoplasms/physiopathology

KW - Recombination, Genetic

KW - Retroviridae/genetics

KW - Risk Assessment

KW - Transgenes

M3 - SCORING: Review article

C2 - 14601513

VL - 5

SP - 458

EP - 462

IS - 5

ER -